In patients with gamma-hydroxybutyrate (GHB) use disorder (GUD), withdrawal can have a fulminant course with rapid progression of severe, potentially life-threatening complications. We present a 45-year old man with severe GHB withdrawal, resistant to conventional treatment with pharmaceutical GHB, high doses of benzodiazepines and baclofen. GHB withdrawal finally responded to thiopental-induced coma therapy, with burst suppression pattern on electroencephalography (EEG). The patient fully recovered, without withdrawal or residual neuropsychiatric symptoms. To our knowledge, this is the first case report in which barbiturates were used to induce a coma to treat severe, treatment resistant GHB withdrawal. This case suggests barbiturate coma therapy might be considered in severe GHB withdrawal which does not respond to conventional treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08897077.2020.1827124 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence.
Int Rev Neurobiol
November 2024
Department of Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Alcohol dependence (AD) significantly impacts public health, affecting 3.4% of people aged 18-64 and contributing to around 12% of overall mortality. Individuals with AD have a markedly reduced life expectancy, dying up to 28 years earlier than the general population.
View Article and Find Full Text PDFReal-world analysis on the use of gamma-hydroxybutyric acid for alcohol withdrawal syndrome in hospitalized patients with diagnosis of cirrhosis.
Intern Emerg Med
September 2024
Toxicology Unit and Poison Control Center, Careggi University Hospital, Florence, Italy.
The present real-world analysis aimed to evaluate and describe the use of gamma-hydroxybutyric acid (GHB) for alcohol withdrawal syndrome (AWS) in hospitalized patients with diagnosis of liver cirrhosis. An 11-year observational retrospective study on patients affected by liver cirrhosis and alcohol use disorder (AUD) was performed using data from the Medical Toxicology Unit of Careggi University Hospital in Florence (Italy). A multivariate logistic regression was performed to estimate the probability of having a CIWA-Ar 3-4 during hospitalization, an AWS length > 36 h, a hospitalization > 9 days, and the probability of developing drowsiness.
View Article and Find Full Text PDFA case of severe and prolonged γ-hydroxybutyrate (GHB) withdrawal syndrome successfully managed with a slow benzodiazepine and baclofen taper.
Drug Alcohol Rev
July 2024
Department of Addiction Medicine, St Vincent's Hospital, Melbourne, Australia.
Article Synopsis
- GHB (γ-hydroxybutyrate) is a powerful substance that affects the brain, similar to alcohol and ecstasy, and can lead to severe withdrawal symptoms that last longer than usually expected.
- A male patient in his 30s, with a long history of GHB use, experienced multiple severe withdrawal episodes over 56 days, requiring extensive medical intervention, including sedation and tracheal intubation.
- The case indicates that managing GHB withdrawal may need a slow tapering process to prevent recurring severe symptoms, suggesting that benzodiazepines and GABA-B receptor agonists are effective treatments.
Treatment of Gamma Hydroxybutyrate Withdrawal in a Pregnant Female: A Case Report.
J Addict Med
June 2024
From the Simon Fraser University, Vancouver, Canada (SJ); FISAM Family and Addiction Medicine Physician, Perinatal Addiction Medical Lead, Island Health, Victoria, Canada (SL); BCCSU Addiction Medicine Fellowship, Island Health, Vancouver Island, Canada (MW); HerWay Home, Victoria, Canada (MW); and Research and Knowledge Translation in Long-Term Care, Island Health, Vancouver Island, Canada (AL).
Article Synopsis
- Gamma hydroxybutyrate (GHB) is commonly misused for its sedative effects, posing a risk for substance use disorder and severe withdrawal symptoms, especially in pregnant women, where guidelines for management are lacking.
- A case involving a 32-year-old pregnant woman showed that using a combination of baclofen and diazepam effectively managed her GHB withdrawal during a 14-day hospital stay, leading to positive outcomes.
- This case emphasizes the need for more research and guidelines on GHB withdrawal treatment in pregnancy, as it provides insight into effective management that could assist healthcare providers in the future.
Individual differences in GHB consumption in a new voluntary GHB self-administration model in outbred rats.
Psychopharmacology (Berl)
March 2024
Donders Institute for Brain Cognition and Behaviour, Department of Cognitive Neuroscience, Radboudumc, 6525 EN, Nijmegen, The Netherlands.
Background And Purpose: The use of the recreational drug gamma-hydroxybutyric acid (GHB) has increased over the past decade, concomitantly leading to a higher incidence of GHB use disorder. Evidence-based treatment interventions are hardly available and cognitive effects of long-term GHB use remain elusive. In order to study the development of GUD and the causal effects of chronic GHB consumption, a GHB self-administration model is required.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!